Health&Beauty- Page 94

The FINANCIAL -- Bayer HealthCare has entered into a new oncology collaboration and licence agreement with Compugen Ltd, according to Bayer AG.

The FINANCIAL -- Light enough to be taken anywhere, razor-thin and stylish, powerful and long-lasting: this is what defines a new generation of laptops – the “ultra- notebooks”.

The FINANCIAL --TRL Krosaki Refractories received the coveted “Golden Peacock Award for Occupational Health and Safety” for the year 2013 from the Institute of Directors, New Delhi. The company has received this prestigious award consecutively twice in a row. It is worthwhile

The FINANCIAL -- The World Bank Board of Executive Directors approved a US$19.8 million grant for the Tajikistan Health Services Improvement Project, which aims to improve maternal and child health outcomes by increasing the coverage and quality of basic primary health care

The FINANCIAL -- Tata Power, India’s large integrated power utility, has continuously endeavoured to improve quality of life of its communities. In another such initiative, Maithon Power Limited, a Joint Venture Company of Tata Power and Damodar Valley Corporation organised a series

The FINANCIAL -- A greater percentage of men who had an incomplete response to as-needed PDE5 inhibitor treatment returned to normal erectile function when given Cialis once daily, compared to placebo, as measured by the erectile function domain of the International Index

The FINANCIAL -- The health care law has emerged as the top concern for small businesses, finds the U.S. Chamber of Commerce’s latest quarterly small business survey.

The FINANCIAL -- Statins — the popular class of cholesterol-lowering drugs used widely to prevent recurrent heart disease and a first event — appear to cause few side effects, according to new research conducted by Huseyin Naci from LSE Health, Jasper Brugts

The FINANCIAL -- Novartis announced today top-line results from the head-to-head Phase III psoriasis study which showed the superiority of secukinumab (AIN457) in clearing skin to Enbrel (etanercept), an anti-tumor necrosis factor (anti-TNF) therapy. In addition, secukinumab (AIN457) met all primary and

The FINANCIAL -- Bayer HealthCare (Bayer) has entered into a new antibody-drug conjugate (ADC) collaboration with Seattle Genetics, Inc. Under the latest relationship, Bayer will get worldwide rights to utilize Seattle Genetics’ auristatin-based ADC technology with antibodies to several oncology targets, according